Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.
Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.
复制标题
达芦那韦、利托那韦和依曲韦林在 HIV 感染女性宫颈阴道液和血浆中的药代动力学。
DOI：
10.1128/aac.00889-10
复制
发表时间：
2011
影响因子：
4.9
通讯作者：
Kashuba,Angela
中科院分区：
文献类型：
--
作者：
Patterson,Kristine;Jennings,Steven;Falcon,Ron;Mrus,Joseph;Kashuba,Angela
我们报告了GRACE研究中达鲁那韦、利托那韦和依特拉韦林在宫颈阴道液和血浆中的药代动力学。8名妇女服用达鲁那韦-利托那韦(600/100毫克)，每天两次，每天两次；两名妇女还接受依特拉韦林(200毫克)，每天2次。4周后收集12h以上的血浆和宫颈阴道液样本，达鲁那韦和依曲韦林宫颈阴道液暴露高于血浆暴露，利托那韦宫颈阴道液暴露低于血浆暴露。达鲁那韦和依特拉韦林在宫颈阴道液中的高暴露证明了对这些药物用于HIV-1预防的进一步评估。
We report darunavir, ritonavir, and etravirine pharmacokinetics in cervicovaginal fluid and blood plasma for women from theGender,RaceandClinicalExperience (GRACE) study. Eight women received darunavir-ritonavir (600/100 mg) twice daily (b.i.d.); two also received etravirine (200 mg) b.i.d. Week 4 paired blood plasma and cervicovaginal fluid samples were collected over 12 h. Darunavir and etravirine cervicovaginal fluid exposures were higher than blood plasma exposures; ritonavir cervicovaginal fluid exposure was lower than blood plasma exposure. The high exposures of darunavir and etravirine in cervicovaginal fluid warrant further evaluation of these drugs for use in HIV-1 prevention.